Guardant Health (NASDAQ:GH) Insider Sells $1,250,800.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) insider John Saia sold 10,000 shares of Guardant Health stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total value of $1,250,800.00. Following the transaction, the insider owned 35,950 shares in the company, valued at $4,496,626. This trade represents a 21.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Trading Up 4.5%

Shares of NASDAQ:GH traded up $5.71 during trading on Thursday, hitting $133.22. 2,997,053 shares of the company’s stock traded hands, compared to its average volume of 2,113,219. Guardant Health, Inc. has a 52 week low of $38.03 and a 52 week high of $133.71. The company has a market cap of $17.66 billion, a price-to-earnings ratio of -39.30 and a beta of 1.48. The company has a 50-day moving average price of $93.34 and a 200-day moving average price of $99.48.

Wall Street Analyst Weigh In

GH has been the subject of a number of analyst reports. Piper Sandler set a $127.00 price objective on shares of Guardant Health in a research report on Thursday, May 21st. Leerink Partners boosted their price target on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Raymond James Financial restated an “outperform” rating and issued a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. Finally, Wells Fargo & Company increased their price target on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.79.

Institutional Trading of Guardant Health

Institutional investors have recently added to or reduced their stakes in the company. Knights of Columbus Asset Advisors LLC bought a new stake in Guardant Health in the 3rd quarter valued at $1,554,000. Erste Asset Management GmbH boosted its stake in Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after purchasing an additional 66,617 shares during the period. Segall Bryant & Hamill LLC boosted its stake in Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares during the period. TD Asset Management Inc boosted its stake in Guardant Health by 16.1% in the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after purchasing an additional 26,210 shares during the period. Finally, GSA Capital Partners LLP lifted its position in shares of Guardant Health by 155.5% during the 3rd quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock valued at $1,373,000 after acquiring an additional 13,378 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.